Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.25 GBX | 0.00% | -0.14% | -23.37% |
May. 15 | Creo Medical on track to break even next year on strong 2023 results | AN |
May. 15 | Creo Medical Group PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | 30.8M 39.23M | Sales 2024 * | 40.37M 51.42M | Capitalization | 123M 156M |
---|---|---|---|---|---|
Net income 2023 | -21M -26.75M | Net income 2024 * | -14M -17.83M | EV / Sales 2023 | 5.2 x |
Net cash position 2023 * | 22.03M 28.06M | Net cash position 2024 * | 132K 168K | EV / Sales 2024 * | 3.04 x |
P/E ratio 2023 |
-6.57
x | P/E ratio 2024 * |
-9.04
x | Employees | 279 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 79.14% |
1 week | -0.14% | ||
Current month | -2.08% | ||
1 month | +0.43% | ||
3 months | +11.90% | ||
6 months | +9.30% | ||
Current year | -23.37% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Craig Gulliford
CEO | Chief Executive Officer | - | 11-12-31 |
President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 16-06-30 |
John Bradshaw
BRD | Director/Board Member | 60 | - |
Craig Gulliford
CEO | Chief Executive Officer | - | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 35.25 | 0.00% | 284,428 |
24-05-23 | 35.25 | -1.40% | 531,885 |
24-05-22 | 35.75 | -2.05% | 747,757 |
24-05-21 | 36.5 | 0.00% | 612,112 |
24-05-20 | 36.5 | +3.40% | 1,346,529 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.37% | 157M | |
+75.35% | 12.55B | |
-23.01% | 7.51B | |
+8.35% | 6.74B | |
+14.40% | 5.47B | |
+32.74% | 4.74B | |
-14.85% | 4.89B | |
-25.57% | 3.7B | |
-23.06% | 2.9B | |
+55.06% | 2.49B |
- Stock Market
- Equities
- CREO Stock